Publication | Closed Access

494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

Anti-inflammatoryActive CrohnImmunologyGastroenterologyWelcome StudyCertolizumab PegolMedicineInflammatory DiseaseDigestive System Diseases